Our results indicate that Ozurdex is a safe and effective second-line treatment for macular edema (ME) due to RVO. In our group, the best functional and anatomical results were achieved two months after application. By the fourth month, a decline in BCVA and an increase in CRT were observed. Between the fifth and sixth month, retreatment was necessary in some patients. Additionally, we confirmed that the greatest rise in IOP occurred two months post-application, which resolved spontaneously by the sixth month. In four patients, IOP values above 30 mmHg were recorded during follow-up, and the intraocular pressure was managed with medication.
Lada et al. (Thu,) studied this question.